- Home
- CAAP vs NAMS Comparison
CAAP vs NAMS Comparison
Compare CAAP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | NAMS |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | Luxembourg | Netherlands |
| Employees | N/A | 100 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CAAP | NAMS |
|---|---|---|
| Price | $25.11 | $29.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $26.73 | ★ $46.75 |
| AVG Volume (30 Days) | 185.9K | ★ 961.2K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.80 | $17.96 |
| Revenue Next Year | $2.36 | $540.65 |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.36 | $21.14 |
| 52 Week High | $30.50 | $42.21 |
Technical Indicators
Market Signals| Indicator | CAAP | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 41.00 |
| Support Level | $24.78 | $29.23 |
| Resistance Level | $26.76 | $37.29 |
| Average True Range (ATR) | 0.66 | 1.88 |
| MACD | 0.04 | -0.42 |
| Stochastic Oscillator | 61.62 | 8.00 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.